SUVEN vs VIMTALABS: Stock Comparison
SUVEN LIFE SCIENCES is the larger company by market capitalisation. SUVEN LIFE SCIENCES shows lower leverage, while VIMTA LABS shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SUVEN leads 3; VIMTALABS leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SUVEN | VIMTALABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Research Analytics & Technology | Healthcare Research Analytics & Technology |
Price
| Metric | SUVEN | VIMTALABS |
|---|---|---|
| Live Price | ₹335.45 | ₹610.15 |
| Day Change | -0.73% | -0.96% |
| Volume | 2.71 L | 1.54 L |
| 52-Week High | ₹403.35 | ₹828.35 |
| 52-Week Low | ₹124.11 | ₹376.05 |
| Distance from 52W High | -16.83% | -26.34% |
Valuation
| Metric | SUVEN | VIMTALABS |
|---|---|---|
| Market Cap | ₹9,486 Cr | ₹2,737 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 14.97x | 0x |
| EPS | ₹-0.61 | ₹4.71 |
| Book Value | ₹22.4 | ₹102.28 |
| Dividend Yield | 0% | 0.33% |
Growth
| Metric | SUVEN | VIMTALABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 3.6% | 16.5% |
| EPS Growth (TTM YoY) | 0% | 14.3% |
| Qtr Sales Growth | 0% | -73.22% |
| Qtr Profit Growth | 87.37% | -72.85% |
Profitability & Leverage
| Metric | SUVEN | VIMTALABS |
|---|---|---|
| ROE | -46.73% | 16.97% |
| ROCE | -47.36% | 17.48% |
| Net Margin | -3,884.13% | 19.03% |
| Operating Margin | -3,881.91% | 25.81% |
| Debt to Equity | 0x | 0.01x |
Shareholding
As of Jul 2026 • change vs previous quarter| Metric | SUVEN | VIMTALABS |
|---|---|---|
| Promoter Holding | 65.47%▼ 4.61 pp | 35.67%▼ 0.18 pp |
| FII Holding | 0.48%▼ 0.09 pp | 4.42%▼ 0.47 pp |
| DII Holding | 2.73%▼ 0.2 pp | 0.37%▲ 0.23 pp |
| Public Holding | 31.32%▲ 4.89 pp | 59.55%▲ 0.43 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUVEN LIFE SCIENCES and VIMTA LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.